EC
ENGN icon

Elmind Capital’s enGene Therapeutics ENGN Stock Holding History

Elmind Capital’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$363K Hold
210,000
– – 0.09% 35
2026
Q1 		$1.43M Hold
210,000
– – 0.41% 31
2025
Q4 		$1.9M Buy
+210,000
New +$1.68M 0.56% 29

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Elmind Capital's ENGN Position: Q2 2026 in Review

Elmind Capital held its enGene Therapeutics (ENGN) position steady in Q2 2026 at 210,000 shares worth $363K. The position accounts for 0.09% of the portfolio, ranked #35.

Elmind Capital first reported a position in ENGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.9M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Elmind Capital held 210,000 shares of enGene Therapeutics worth $363K as of Q2 2026.
  • Elmind Capital left its enGene Therapeutics share count unchanged in Q2 2026.
  • enGene Therapeutics made up 0.09% of Elmind Capital's portfolio in Q2 2026, its #35 holding.
  • Elmind Capital first reported a position in enGene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Elmind Capital's enGene Therapeutics position peaked at $1.9M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.